Delcath Systems Reports Positive Data From Ongoing Phase II Multi-Histology Trial At The Second International Symposium On Regional Cancer Therapies

Tue, 27 Feb 2007 02:00 PM EST

... Delcath Systems, Inc. (Nasdaq: DCTH) today reported encouraging interim results from its ongoing Phase II multi-histology trial of the treatment of unresectable primary and metastatic cancers of the liver using the Delcath system with melphalan. [click link for full article] ...